Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway

References

• Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer. 2008;112(4):737–747.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434.
   PubMed Web of Science ®Google Scholar
• Lee A, Djamgoz M. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–122.
   PubMed Web of Science ®Google Scholar
• Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016;31:97–103.
   PubMed Web of Science ®Google Scholar
• Agarwal G, Nanda G, Lal P, et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: does the survival vary for all stages? World J Surg. 2016;40(6):1362–1372.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia.. 2004;9(1):95–104.
   PubMed Web of Science ®Google Scholar
• Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. JCO. 2019;37(14):1169–1178.
   PubMed Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–6182.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee WK, Kang CW, et al. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett. 2018;417:131–140.
   PubMed Web of Science ®Google Scholar
• Li XY, Seebacher NA, Garbutt C, et al. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell Death Dis.. 2018;9(5):446–459.
   PubMed Web of Science ®Google Scholar
• Iyengar M, O’Hayer P, Cole A, et al. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget. 2018;9(21):15658–15672.
   PubMedGoogle Scholar
• Xiong YD, Li TQ, Assani G, et al. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo. Biomed Pharmacother. 2019;112:108602
   PubMed Web of Science ®Google Scholar
• Naz S, Sowers A, Choudhuri R, et al. Abemaciclib, a selective CDK4/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer in vitro and in vivo. Clin Cancer Res. 2018;24(16):3994–4005.
   PubMed Web of Science ®Google Scholar
• Olmez I, Brenneman B, Xiao AZ, et al. Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms. Clin Cancer Res.. 2017;23(22):6958–6968.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012;287(34):29075–29087.
   PubMed Web of Science ®Google Scholar
• Fang H, Huang D, Yang F, et al. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Res Treat. 2018;168(2):287–297.
   PubMed Web of Science ®Google Scholar
• Rondla R, PadmaRao LS, Ramatenki V, et al. Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach. Comput Biol Chem. 2017;71:224–229.
   PubMed Web of Science ®Google Scholar
• Rocca A, Schirone A, Maltoni R, et al. Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol.. 2017;9(2):83–105.
   PubMed Web of Science ®Google Scholar
• Poratti M, Marzaro G. Third-generation CDK inhibitors: a review on the synthesis and binding modes of palbociclib, ribociclib and abemaciclib. Eur J Med Chem. 2019;172:143–153.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015;21(21):4760–4766.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Walker AJ, Wedam S, Amiri-Kordestani L, et al. FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clinic Cancer Res. 2016;22(20):4968–4972.
   PubMed Web of Science ®Google Scholar
• Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166(1):41–54.
   PubMed Web of Science ®Google Scholar
• Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 Inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23(18):5561–5572.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
   PubMed Web of Science ®Google Scholar
• Matsushime H, Quelle DE, Shurtleff SA, et al. D-type cyclin-dependent kinase-activity in mammalian-cells. Mol Cell Biol. 1994;14(3):2066–2076.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353–367.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13(9):2184–2193.
   PubMed Web of Science ®Google Scholar
• Tao YF, Wang NN, Xu LX, et al. Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells. Cancer Cell Int. 2017;17(1):35.
   PubMed Web of Science ®Google Scholar
• Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 1998;395(6699):237–243.
   PubMed Web of Science ®Google Scholar
• Arima Y, Hayashi N, Hayashi H, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer. 2012;130(11):2568–2579.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251–3262.
   PubMed Web of Science ®Google Scholar
• Shin E, Jung WH, Koo JS. Expression of p16 and pRB in invasive breast cancer. Int J Clinic Exp Pathol. 2015;8(7):8209–8217.
   PubMed Web of Science ®Google Scholar
• Wong HH, Halford S. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol. 2015;16(13):1287–1288.
   PubMed Web of Science ®Google Scholar
• Seront E, Schmitz S, Papier M, et al. Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck. Front Oncol. 2019;9:155.
   PubMed Web of Science ®Google Scholar
• Doi T, Hewes B, Kakizume T, et al. Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors. Cancer Sci. 2018;109(1):193–198.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, LoRusso PM, DeMichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clinic Cancer Res. 2012;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Day ML, Foster RG, Day KC, et al. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J Biol Chem. 1997;272(13):8125–8128.
   PubMed Web of Science ®Google Scholar
• Valenzuela CA, Vargas L, Martinez V, et al. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res. 2017;360(2):390–396.
   PubMed Web of Science ®Google Scholar